Evidence map›Paper›PMID 3278006›Full record

ArticleThe Journal of clinical investigation1988

Acetylated lipoproteins impair erythroid growth factor release from endothelial cells.

N Dainiak, H B Warren, S Kreczko, M A Riordan, L Feldman, J Lawler, A M Cohen, P F Davies

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 1988. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells.Proceedings of the National Academy of Sciences of the United States of America · 1990
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

N DainiakDepartment of Medicine, St. Elizabeth's Hospital, Boston, MA 02135.
H B Warren
S Kreczko
M A Riordan
L Feldman
J Lawler
A M Cohen
P F Davies
Tufts University · USSt. Elizabeth's Hospital · PK

Funding

VCAM-1 IN CHRONIC INFLAMMATORY AND IMMUNE PROCESSESP01HL036028 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LUSCINSKAS, FRANCIS W. · 1985 to 2013
$32.1M
CONTROL OF ERYTHROPOIESIS BY HORMONES AND PARACRINESR01AM027071 · AM · ST. ELIZABETH'S MEDICAL CENTER OF BOSTON · PI DAINIAK, NICHOLAS J · 1985 to 1985
–
ERYTHROPOIESIS BY CELL SURFACE COMPONENTSR01AM031060 · AM · ST. ELIZABETH'S MEDICAL CENTER OF BOSTON · PI DAINIAK, NICHOLAS J · 1985 to 1985
–
NHLBI NIH HHS HL-36028NIADDK NIH HHS AM-27071NIADDK NIH HHS AM-31060
6 · The paper itself

Abstract

Endothelial cells are a known source of hematopoietic growth-enhancing factors, including platelet-derived growth factor (PDGF). In addition, endothelium interacts directly with plasma lipoproteins which have been shown to modulate hematopoiesis. To determine the relationship of these properties, we measured the release of an erythroid growth-enhancing factor from bovine endothelial cells under lipid-loaded and control conditions. Human bone marrow cells cultured under serum-free conditions form more erythroid, granulocyte/macrophage, and mixed hematopoietic colonies when supplemented with endothelial cell-conditioned medium (ECCM) than do controls (P less than 0.05). The activity is expressed over a wide range of erythropoietin, lymphocyte-conditioned medium (LCM), recombinant human interleukin-3, and colony-stimulating factor (CSF) concentrations, and is related to ECCM dose. In contrast, enhancing activity in ECCM prepared with 0-400 micrograms/ml acetylated low density lipoproteins (AcLDL) or native LDL is diminished to 0% in a dose-dependent fashion (relative to ECCM from unexposed cells or from cells incubated with very low density lipoproteins, P less than 0.05). Upon dilution, medium prepared from cells incubated with LDL shows a rightward shift in the dose-response curve for erythroid colony formation, while that prepared from AcLDL loaded cells demonstrates a downward shift, indicating that the inhibitory activities are kinetically distinct. Delipidation of ECCM prior to addition to marrow culture removes the inhibitory action of native LDL (P less than 0.05) but not that of AcLDL (P greater than 0.10). Immunochemical analysis suggests that the erythropoietic activity in ECCM is unrelated to that of PDGF, recombinant human CSF, and erythroid burst-promoting activity (BPA) present in LCM. This conclusion is supported by Northern blot analysis of endothelial cells using a cDNA probe for the v-sis homologue of the PDGF beta chain and by immunoprecipitation of metabolically labeled PDGF. The relative amounts of c-sis transcripts and of secreted PDGF were similar in endothelial cells incubated with or without AcLDL. We conclude that AcLDL impair the synthesis or release of an erythropoietic growth-enhancing factor(s) which is biologically distinct from PDGF and BPA present in LCM.

Indexed as

ErythropoiesisAcetylationAnimalsCattleCholesterolColony-Forming Units AssayCulture MediaDrug InteractionsEndothelium, VascularGene Expression RegulationGrowth SubstancesHematopoietic Cell Growth FactorsHumansLipid MetabolismLipidsLipoproteins, LDLCholesterolCulture MediaGrowth SubstancesHematopoietic Cell Growth FactorsLipidsLipoproteins, LDLPlatelet-Derived Growth Factor

Identifiers

PMID3278006
PMCPMC442534
OpenAlexW2048631071

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.